Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study

Herbst, RS; Garon, EB; Kim, DW; Cho, BC; Perez-Gracia, JL; Han, JY; Arvis, CD; Majem, M; Forster, MD; Monnet, I; Novello, S; Szalai, Z; Gubens, MA; Su, WC; Ceresoli, GL; Samkari, A; Jensen, EH; Lubiniecki, GM; Baas, P

Herbst, RS (corresponding author), Yale Sch Med, Comprehens Canc Ctr, 333 Cedar St,WWW221, New Haven, CT 06520 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (14): 1580

Abstract

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索